Methylglyoxal-modified arginine residues — a signal for receptor-mediated endocytosis and degradation of proteins by monocytic THP-1 cells

This publication has 37 references indexed in Scilit:

• Molecular characteristics of methylglyoxal-modified bovine and human serum albumins. Comparison with glucose-derived advanced glycation endproduct-modified serum albumins
  Protein Journal, 1995
• Advanced glycation end products contribute to amyloidosis in Alzheimer disease.
  Proceedings of the National Academy of Sciences, 1994
• beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis.
  Journal of Clinical Investigation, 1993
• Angiogenic Effects of Advanced Glycation End Products of the Maillard Reaction on Cultured Human Umbilical Cord Vein Endothelial Cells
  Biochemical and Biophysical Research Communications, 1993
• Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus.
  Journal of Clinical Investigation, 1993
• Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications.
  Proceedings of the National Academy of Sciences, 1992
• Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins.
  Journal of Clinical Investigation, 1992
• Role of Glycation in Modification of Lens Crystallins in Diabetic and Nondiabetic Senile Cataracts
  Diabetes, 1991
• Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging.
  Proceedings of the National Academy of Sciences, 1990
• High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules.
  Proceedings of the National Academy of Sciences, 1985